Skip to main content
Frontier Biotechnologies Inc. logo

Frontier Biotechnologies Inc. — Investor Relations & Filings

Ticker · 688221 ISIN · CNE100005XF5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2021-03-30 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688221

About Frontier Biotechnologies Inc.

https://www.frontierbiotech.com/

Frontier Biotechnologies Inc. is a biopharmaceutical company focused on the research, development, and commercialization of innovative medicines, particularly in the field of anti-infectives. The company's flagship product is albuvirtide, a long-acting HIV fusion inhibitor administered via injection. This therapeutic represents a significant advancement in HIV management by providing a long-acting alternative to daily oral regimens. Frontier Biotechnologies maintains a diverse pipeline of clinical-stage candidates, including protease inhibitors developed for the treatment of COVID-19. The company leverages its proprietary technology platforms to develop long-acting peptide drugs and small molecule therapeutics targeting unmet medical needs in infectious diseases and chronic conditions. Its core operations encompass the full drug development lifecycle, from discovery and clinical trials to manufacturing and commercial distribution.

Recent filings

Filing Released Lang Actions
毕马威华振会计师事务所（特殊普通合伙）关于前沿生物药业（南京）股份有限公司2020年度非经营性资金占用及其他关联资金往来情况的专项说明
Audit Report / Information Classification · 95% confidence The document is a special explanatory statement regarding non-operating fund occupation and other related party fund transactions for the year 2020 of a listed company, prepared in accordance with requirements from the China Securities Regulatory Commission and the State-owned Assets Supervision and Administration Commission. It includes detailed tables of fund occupation and related party transactions, signed by the accounting firm KPMG Huazhen LLP and company officials. The document references the audited financial statements for 2020 but is not itself the full annual report or audit report. It is a standalone audit-related explanatory statement focusing on specific regulatory compliance about related party transactions and fund occupation, which fits the definition of an Audit Report / Information (AR). The document length (7204 characters) and content confirm it is not a brief announcement or a certification letter but a substantive audit-related report.
2021-03-30 Chinese
前沿生物监事会关于2021年限制性股票激励计划首次授予激励对象名单的核查意见（截止授予日）
Share Issue/Capital Change Classification · 95% confidence The document is a verification opinion from the Supervisory Board regarding the initial grant list of restricted stock incentive plan for 2021. It discusses compliance with laws and regulations related to stock incentives, qualifications of incentive recipients, and details about the grant date and price. This is a formal announcement related to a capital change event involving restricted stock grants. It is not a full financial report, audit, or management discussion, nor is it a voting result or meeting material. The content fits best under Share Issue/Capital Change announcements, as it relates to the issuance of restricted stock incentives.
2021-03-30 Chinese
前沿生物关于第二届董事会第十八次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors providing prior approval opinions related to the company's board meeting agenda, specifically regarding the reappointment of the accounting firm KPMG Huazhen for audit services. It references compliance with company law and securities law, and the independent directors' review and endorsement of audit-related matters. The document is short (570 characters) and does not contain actual financial statements or detailed audit results. It is not the audit report itself but an opinion related to audit matters for board consideration. Therefore, it fits best under Board/Management Information (MANG), as it concerns board meeting matters and management-level approvals rather than a full audit report or annual report.
2021-03-30 Chinese
前沿生物关于调整2021年限制性股票激励计划相关事项的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding adjustments to the 2021 restricted stock incentive plan of the company. It details board and supervisory approvals, adjustments to the list of incentive recipients, legal and financial advisor opinions, and compliance with relevant laws and regulations. The document is a formal announcement about changes to a stock incentive plan, not a full report or financial statement. It does not contain financial results or detailed financial data but rather governance and management decisions related to equity incentives. This fits best under the category of Regulatory Filings (RNS) as it is a regulatory announcement about corporate governance and equity incentive adjustments without being a full management report or remuneration report.
2021-03-30 Chinese
前沿生物关于召开2020年年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2020 annual performance explanation meeting (业绩说明会) for the company 前沿生物药业（南京）股份有限公司. It references that the 2020 annual report has already been disclosed on March 31, 2021, and invites investors to participate in a web-based interactive session on April 7, 2021. The document does not contain the actual annual report or financial data but is a notice about the meeting to discuss the annual results. The document length is short (953 characters), and it serves as an announcement rather than the report itself. Therefore, it fits best under Investor Presentation (IP) as it is a detailed presentation event for investors focusing on financials and company performance.
2021-03-30 Chinese
前沿生物关于第二届董事会第十八次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the 18th meeting of the second board of directors of the company. It includes details about the approval of various reports such as the 2020 annual general manager work report, board work report, audit committee report, independent director report, financial statements, budget report, fundraising usage report, annual report, profit distribution plan, internal control self-evaluation report, and appointment of auditors. It also mentions the submission of these reports to the shareholders' meeting for approval. The document is primarily about board meeting decisions and announcements related to management and governance matters, including appointments and financial budget approvals. It does not contain the full annual report or financial statements themselves but references their availability on the stock exchange website. Therefore, it is best classified as Board/Management Information (MANG). The document length (4751 characters) and content confirm it is not a full annual report or audit report but a board meeting resolution announcement.
2021-03-30 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.